VAN L. LACKEY, M.D.

JACKSON, MS

Research Active
Internal Medicine - Medical Oncology NPI registered 21+ years 1 publication 2018 – 2018 NPI: 1740284389
Internal Medicine - Medical Oncology Internal Medicine - Hematology & Oncology

Practice Location

1227 N STATE ST
JACKSON, MS 39202-2002

Phone: (601) 355-2485

What does VAN LACKEY research?

Dr. Lackey studies the intersection of rheumatology and women's reproductive health, particularly for women who are prescribed teratogenic medications—those that can adversely affect fetal development. He explores how effectively healthcare providers communicate contraception options and document their use among these patients. By ensuring that women have access to comprehensive contraceptive information, he aims to reduce the risk of unintended pregnancies and improve overall health outcomes.

Key findings

  • After implementing improvements in communication, the documentation of contraceptive methods among patients rose from 46% to 64%.
  • The study indicates that proactive discussions about contraception significantly increase women's awareness and use of effective contraceptive methods while on teratogenic medications.
  • Ensuring documentation of contraception in rheumatology clinics is crucial for the safety of women of childbearing age taking potentially harmful medications.

Frequently asked questions

Does Dr. Lackey study women's health?
Yes, he specifically focuses on women's reproductive health, especially regarding the use of potentially harmful medications.
What is the significance of teratogenic medications?
Teratogenic medications can cause developmental issues in a fetus, making it crucial for women on these drugs to effectively manage their reproductive health.
How does Dr. Lackey's work help women?
His research helps improve communication and documentation regarding contraception, ensuring that women using these medications have the necessary support to prevent unintended pregnancies.

Publications in plain English

Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic.

2018

BMJ open quality

Sadun RE, Wells MA, Balevic SJ, Lackey V, Aldridge EJ +5 more

Plain English
This study looked at how well doctors in a rheumatology clinic documented and discussed contraception options with women taking medications that could harm a fetus. Initially, only 46% of patients had their contraceptive methods documented, and after the clinic made improvements, that rate rose to 64%. This matters because women on these medications at risk of unintended pregnancies need better support to ensure their safety and health. Who this helps: This helps women of childbearing age taking teratogenic medications.

PubMed

Frequent Co-Authors

Rebecca E Sadun Melissa A Wells Stephen J Balevic Erica J Aldridge Nicholas Holdgagte Samya Mohammad Lisa G Criscione-Schreiber Megan E B Clowse Mamata Yanamadala

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.